Table 2

Comparison of Data Among IL28B minor allele carriers who achieved SVR or not
SVR group (n=4) Non-SVR group (n=35) Odds ratio P value 95% CI
Age ≥60 (yes / no), n 1 / 3 23 / 12 0.17 n.s 0.01 – 1.85
Sex (male / female), n 2 / 2 19 / 16 0.84 n.s 0.11 – 6.67
Hemoglobin level (g/dl), mean ± SD 13.2 ± 0.8 12.9 ± 0.3 - n.s -
Platelet count (x104/μl), mean ± SD 7.9 ± 0.9 8.0 ± 0.3 - n.s -
Pretreatment viral load (logIU/mL), mean ± SD 6.5 ± 0.4 6.3 ± 0.1 - n.s -
HCV genotype (1/2), n 3 / 1 34 / 1 11.3 0.06 0.56 - 230
splenectomy (yes / no), n 3 / 1 8 / 27 10.1 <0.05 0.92-112
ITPA genotype (major/minor), n 3 / 1 26 / 9 1 n.s 0.09 – 11.2

CI; confidence interval, HCV; hepatitis C virus, IL28B; interleukin-28B, ITPA; inosine triphosphate pyrophosphatase, n.s ; not significant, Spx; splenectomy.

Motomura et al.

Motomura et al. BMC Gastroenterology 2012 12:158   doi:10.1186/1471-230X-12-158

Open Data